MA34084B1 - Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant - Google Patents

Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant

Info

Publication number
MA34084B1
MA34084B1 MA35241A MA35241A MA34084B1 MA 34084 B1 MA34084 B1 MA 34084B1 MA 35241 A MA35241 A MA 35241A MA 35241 A MA35241 A MA 35241A MA 34084 B1 MA34084 B1 MA 34084B1
Authority
MA
Morocco
Prior art keywords
type
composition contains
amyloid peptide
beta amyloid
plus virus
Prior art date
Application number
MA35241A
Other languages
Arabic (ar)
English (en)
Inventor
Peter Ulrich
Katja Baer
Georges Imbert
Marie-Jose Hoellinger
Marie-Emmanuelle Riviere
Ana Graf
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42285305&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34084(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34084B1 publication Critical patent/MA34084B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des compositions comprenant une construction comprenant le peptide ?ß1-6 et un adjuvant pharmaceutiquement acceptable, destinées au traitement de patients souffrant de démence, en particulier la démence de type alzheimer. Dans un mode de réalisation, la construction contenant le peptide ?ß1-6 est constituée par une particule de type virus (vlp) du bactériophage à arn qß couplée chimiquement audit peptide ?ß1-6.
MA35241A 2010-03-29 2011-03-28 Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant MA34084B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158273 2010-03-29
PCT/EP2011/054735 WO2011120924A1 (fr) 2010-03-29 2011-03-28 Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant

Publications (1)

Publication Number Publication Date
MA34084B1 true MA34084B1 (fr) 2013-03-05

Family

ID=42285305

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35241A MA34084B1 (fr) 2010-03-29 2011-03-28 Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant

Country Status (23)

Country Link
US (4) US20130011431A1 (fr)
EP (1) EP2552489A1 (fr)
JP (2) JP6088422B2 (fr)
KR (1) KR20130018407A (fr)
CN (2) CN102834118A (fr)
AR (1) AR080810A1 (fr)
AU (1) AU2011234656B2 (fr)
BR (1) BR112012024708A2 (fr)
CA (1) CA2793580A1 (fr)
CL (1) CL2012002685A1 (fr)
CO (1) CO6630127A2 (fr)
EC (1) ECSP12012180A (fr)
GT (1) GT201200265A (fr)
IL (1) IL221540B (fr)
MA (1) MA34084B1 (fr)
MX (1) MX2012011340A (fr)
NZ (1) NZ601729A (fr)
PE (1) PE20130642A1 (fr)
RU (1) RU2603486C2 (fr)
SG (2) SG183806A1 (fr)
TN (1) TN2012000431A1 (fr)
TW (2) TW201138805A (fr)
WO (1) WO2011120924A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195257B2 (en) 2013-07-28 2019-02-05 Qantu Therapeutics, Inc. Vaccine formulations comprising quillaja desacylsaponins and beta amyloid peptides or tau protein to induce a Th2 immune response
AU2015254665A1 (en) * 2014-04-29 2016-11-10 Affiris Ag Treatment and prevention of alzheimer's disease (AD)
WO2015165961A1 (fr) 2014-04-29 2015-11-05 Affiris Ag Traitement et prévention de la maladie d'alzheimer
WO2015165974A1 (fr) * 2014-04-29 2015-11-05 Affiris Ag Traitement et prévention des démences associées aux dépôts amyloïdes, de préférence la maladie d'alzheimer
WO2015165971A1 (fr) * 2014-04-29 2015-11-05 Affiris Ag Traitement et prévention de la maladie d'alzheimer
CA2946928C (fr) * 2014-04-29 2023-01-31 Affiris Ag Traitement et prevention de la maladie d'alzheimer
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
AU8298298A (en) * 1997-07-08 1999-02-08 Chiron Corporation Use of submicron oil-in-water emulsions with dna vaccines
RU2323002C2 (ru) * 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
BR0312792A (pt) * 2002-07-19 2005-05-03 Cytos Biotechnology Ag Composições de vacinas contendo séries antigênicas de amilóide beta1-6
CN100409896C (zh) * 2003-03-31 2008-08-13 姚志彬 一种老年性痴呆疫苗及其制备方法
MX2007003171A (es) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CN101318015A (zh) * 2008-06-25 2008-12-10 中山大学 老年性痴呆重组蛋白疫苗及其制备方法

Also Published As

Publication number Publication date
PE20130642A1 (es) 2013-06-19
US20130011431A1 (en) 2013-01-10
ECSP12012180A (es) 2012-10-30
AU2011234656B2 (en) 2013-08-01
CO6630127A2 (es) 2013-03-01
CN102834118A (zh) 2012-12-19
WO2011120924A1 (fr) 2011-10-06
RU2603486C2 (ru) 2016-11-27
AR080810A1 (es) 2012-05-09
CL2012002685A1 (es) 2013-01-25
JP6088422B2 (ja) 2017-03-01
TW201618806A (zh) 2016-06-01
GT201200265A (es) 2014-03-14
TN2012000431A1 (en) 2014-01-30
JP2013523682A (ja) 2013-06-17
SG183806A1 (en) 2012-10-30
AU2011234656A1 (en) 2012-10-11
NZ601729A (en) 2013-10-25
TW201138805A (en) 2011-11-16
CN104436212A (zh) 2015-03-25
EP2552489A1 (fr) 2013-02-06
US20160101167A1 (en) 2016-04-14
US20140348871A1 (en) 2014-11-27
CA2793580A1 (fr) 2011-10-06
US20150297692A1 (en) 2015-10-22
RU2012145734A (ru) 2014-05-10
SG10201505374TA (en) 2015-08-28
KR20130018407A (ko) 2013-02-21
JP2017008035A (ja) 2017-01-12
BR112012024708A2 (pt) 2016-06-07
IL221540B (en) 2018-11-29
MX2012011340A (es) 2012-11-16

Similar Documents

Publication Publication Date Title
MA34084B1 (fr) Composition comprenant le peptide amyloïde bêta 1-6 couplé à une particule de type virus et un adjuvant
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201171388A1 (ru) Гуманизированные антитела, специфичные к протофибриллярной форме бета-амилоидного пептида
MY181969A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
GB201118656D0 (en) New compounds
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
NZ712207A (en) Tetrahydropyrrolothiazine compounds
CL2008003593A1 (es) Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EA201270722A1 (ru) Формы рифаксимина и их применение
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
SG179095A1 (en) Novel assay for the detection of amyloid beta peptides
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
CL2009000119A1 (es) Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
UA108636C2 (xx) Пептид
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
EA201300421A1 (ru) Комбинированная терапия для лечения инфекции hcv
IN2015DN00515A (fr)
EA201391097A1 (ru) СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА